Compare Nomura Holdings Inc (NMR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Tango Therapeutics Inc. — how do they compare? Nomura Holdings Inc trades at $9.2 (market cap $28.01B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nomura Holdings Inc is far larger — about 7.5× Tango Therapeutics Inc.'s market cap, and Nomura Holdings Inc pays a 3.38% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 56 Days and Tango Therapeutics Inc. for 0 Days on average.
| NMR | TNGX | |
|---|---|---|
Market Cap | $28.01B | $3.75B |
Volume | 686,801 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $10.86 | $32.90 |
52-Week Low | $6.92 | $7.50 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $38.48T | $2.77B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.26, down 3.24% with bearish technical signals. The stock shows mixed earnings performance with recent misses but strong revenue growth from $1.66T in 2025. Valuation appears attractive with P/E of 11.37 and P/B of 1.16, while analyst sentiment leans cautious with 67% hold ratings. Recent Zacks coverage highlights momentum potential and hammer chart pattern formation.
Outlook remains balanced with fundamental strength in profitability margins (20.4% net income) offset by technical weakness. Investment opportunity lies in discounted valuation amid earnings growth, while risks include cash flow volatility and rising debt levels. The stock requires careful monitoring of Q3 2026 earnings results for directional clarity.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
